Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double‐blind clinical trial

Purslane ( Portulaca oleracea L.) is the richest green leafy vegetable source of omega‐3, especially alpha linolenic acid (ALA). Experimental studies have shown beneficial effects of purslane extract on liver enzymes. The aim of the present study was to examine the effect of purslane hydroalcohoic extract in patients with non‐alcoholic fatty liver disease (NAFLD). In a randomized double‐blinded clinical trial, 74 patients were randomly assigned to receive either 300 mg purslane extract or placebo capsules for 12 weeks. Compared with baseline, alanine aminotransferase (ALT) (−9 [−17, 0.50] mg/dl; p = .007), aspartate aminotransferase (AST) (−4 [−10, −0.50] mg/dl; p = .001), gamma glutamyltransferase (GGT) (−6.21 ± 9.85 mg/dL; p < .001), fasting blood glucose (FBG) (−8 [−11, −1.50] mg/dl; p < .001) insulin resistance (−0.95 ± 2.23; p = .020), triglyceride (−20 [−67.50, 3.50] mg/dl; p = .010), and low‐density lipoprotein cholesterol (LDL‐C) (−5 [−12, −1] mg/dl; p < .001) decreased significantly in the purslane group. At the end of study, no significant changes were observed in liver steatosis grade, insulin, liver enzymes, total bilirubin, lipid profile, and blood pressure between the two groups. The findings of our study show that purslane extract at the dose of 300 mg/day for 12 weeks has no significant effects on liver enzymes, lipid profile, and glycemic indices in patients with NAFLD.